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Abstract 
AIM: This study aims to evaluate the methods of treatment of the thoracic part of oesophagal cancer and to 
predict the results of treatment depending on the factors of the prognosis. 
MATERIALS AND METHODS: The results of treatment of 366 patients with cancer of the thoracic part of the 
oesophagus for 10 years (2007-2016) by the department of thoracic oncology of the Karaganda oncological 
dispensary were studied. 
RESULTS: The overall five-year survival rate, regardless of the method of treatment, was only 8.72% (28 of 321), 
and in the 6-10 year period 8.41% (27 of 321) lived, p < 0.05. Analysis of the overall survival of patients 
with cancer of the thoracic part of oesophagus showed that the method of treatment does not have a significant 
effect on life expectancy. A multivariate analysis of 19 grades that affect the prognosis of the disease was carried 
out. 
CONCLUSION: Radical type of treatment of the middle and lower thoracic oesophagus is surgical, in which the 
median of cumulative survival is 19 months. Traditional radiotherapy should be used in a limited way, as it is 
palliative, with a median survival of no more than 9 months. The leading factor in the prognosis for thoracic part of 
oesophagal cancer is the presence of regional metastases, on which the choice of method of treatment depends. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The incidence of oesophagal cancer in 
Kazakhstan remains high, amounting to 7.7 per 100 
thousand, which is 1.2 times more than in the Russian 
Federation. Even though the population of the 
Russian Federation is 10 times more than in 
Kazakhstan. Mortality from this pathology in 
Kazakhstan takes the 4th place, accounting for 5.8%. 
The incidence of oesophagal cancer in the Karaganda 
region is 8.8 per 100 thousand populations, which is 
1.3 higher than in the Republic of Kazakhstan. 
The main cause of high mortality up to one 
year after diagnosis is late detection of oesophagal 
cancer; mortality is 65% [1]. Many researchers [2], [3] 
note that the majority of patients at the beginning of 
treatment have stage III-IV of the tumour process in 
65-75% of cases. The presence of common forms of 
oesophagal cancer at the time of treatment creates 
certain difficulties in the choice of therapy. Many 
patients are unresectable due to the high prevalence 
of the tumour process [4], competing comorbidities. In 
20% of cases after radical treatment, local 
recurrences of a tumour in the anastomosis was 
detected. 
P.A. Herzen (Moscow) [5] has developed the 
following program for the treatment of oesophagal 
cancer. At stage I-II and in the absence of 
metastases, an organ-preserving treatment is 
proposed: electro- and laser destruction of the tumor 
with the administration of the “Photochem” and 
“Photosens” preparations, with locally advanced 
esophageal cancer, i.e. in stage III, in view of the 
severity of the initial condition (significant loss in 
weight, severe dysphagia, and dehydration), at the 
first stage, gastrostomy is performed according to our 
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own method with revision of paracardial, paraaortal 
metastasis areas and their removal. According to 
reports [5], the imposition of gastrostomy allows for 
adequate rehabilitation of the patient and to prepare 
for a radical operation. In the presence of a 
decompensated initial state, simultaneous resection of 
the oesophagus with esophagoplasty by an 
isoperistaltic stem from the greater curvature of the 
stomach is recommended. In doubtful cases, when 
the initial condition of the patient is assessed as 
serious, then dobromyslov's two-stage operation-
Toreka is performed. Delayed esophagoplasty is used 
6 months after the first. According to L.D. Roman et 
al., [3], the surgical method of treating cancer of the 
oesophagus remains the main method, despite the 
success of chemoradiotherapy. So R.Kube et al., [6] 
consider the results of 5-year survival during 
chemoradiation therapy of oesophagal cancer to be 
doubtful. According to D. Karpov et al., [7], with the 
common and neglected forms of oesophagal cancer, 
palliative surgical and endoscopic methods must be 
supplemented with radiation therapy. At the same 
time, Chissov V.I., Daryalova S.L. [8] believe that 
chemotherapy and radiation methods rarely regress a 
tumour, and the life expectancy after it does not 
exceed 13 months. 
Other researchers [9], on the contrary, note 
that neoadjuvant radiochemotherapy is a promising 
method, and in 10–20% of cases complete regression 
can be achieved. Orringer M.B. et al. used a complex 
method of treatment of common forms of oesophagal 
cancer, and in 52% of patients in the postoperative 
period, no complications were noted [9]. 
Thus, the prospects for chemoradiation 
therapy for cancer of the thoracic oesophagus are 
extremely limited if they are not complemented by 
surgical intervention. 
The purpose of this study is to evaluate the 
treatment of cancer of the thoracic oesophagus and to 
predict the results of treatment depending on the 
prognostic factors. 
 
 
Material and Methods 
 
The results of treatment of cancer of the ore 
oesophagus for 10 years (2007-2016) were analysed 
based on the materials of the Department of Thoracic 
Oncology of the Karaganda Oncologic Dispensary. 
The results of treatment of 366 patients with thoracic 
part of oesophagal cancer were studied. In the 
analysed material (Figure 1) men prevailed than 
women, the ratio was 1.6: 1 (p ≤ 0.05). 
Among the patients, the inhabitants of rural 
areas prevailed, 70.21 ± 2.4% (257), compared with 
urban areas, 29.78 ± 2.4% (109) p ≤ 0.05. 
According to the ethnic composition (Figure 2) 
of the patients, it turned out that the majority were (p ≤ 
0.05) of the indigenous people of Kazakhs 71.58 ± 
2.36% (262), slavs-only 19.39 ± 2.07% ( 71) while 
others were identified at 9.03 ± 1.5% (33). 
 
Figure 1: Sex composition of patients 
 
Most often, tumours were localised in the 
middle part of thoracic part of the oesophagus -
58.74% (215), then in the lower part, 34.15 (125). 
According to the prevalence of the tumour process 
(Table 1), patients were distributed according to the 
international classification of staging (TNM, 2011) as 
follows, stage IIa, T3N0M0, 59.56% (218), then stage 
IIIa, T4aN0M0, 16.93% (62) and Ib stage T2N0M0 
was only 10.65% (39) p < 0.05. 
 
Figure 2: Ethnic composition of patients 
 
Among the histological forms, squamous cell 
carcinoma without keratinisation with keratinisation 
dominated, respectively -65.30% (239) and 27.05% 
(99). Rare forms such as adenocarcinoma and 
undifferentiated cancer did not exceed, respectively, 
5.46% (20) and 2.19% (8) p < 0.05. 
Table 1: Stage cancer of the thoracic part of the oesophagus 
№ Stage TNM stage 
Abs. 
number 
Per cent,  
% 
Mistake,  
m 
1 I a T1N0M0 4 1.09 0.54 
2 I b T2N0M0 39 10.65 1.61 
3 II a T3N0M0 218 59.56 2.57 
4 II b T1-2N1M0 9 2.46 0.81 
5 III a T4aN0M0, T3N1M0, T1-2N2M0 62 16.94 1.96 
6 III b T3N2M0 30 8.20 1.43 
7 III c T4aN1-2M0, T4bN1-3M0, T1-4N3M0 4 1.10 0.54 
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Regional metastases were detected in 
paraesophageal lymph nodes in 13.11% (48) cases, 
paracardial-12.57% (46). Without metastases, there 
were 35.25% (129) patients, and metastases in 39.07 
(143) patients were not verified, which, based on X-
ray data and computed tomography, enlarged lymph 
nodes were detected, and they were subjected to 
radiation therapy. All patients were distributed 
according to the treatment plan, taking into account 
the prognosis factors for 3 groups: 
Group 1-surgical treatment of 45.36% (166); 
Group 2-radical radiation therapy 41.53% 
(152); 
Group 3-combined method (preoperative 
course of radiation therapy + surgery) 13.11% (48). 
Surgical intervention was carried out in two 
ways-Subtotal resections of the mid-thoracic part of 
the oesophagus with bizonal lymph dissection-Lewis 
operation-46.45% (170), Garlock operation-resection 
of the lower thoracic part of the oesophagus with 
resection of the proximal stomach with bizonal lymph 
dissection-12.02 % (44). 
With the traditional method of operation 
according to the Lewis method, after laparotomy, 
mobilisation of the stomach with the intersection of the 
right ligament of the diaphragm with preservation of 
the right gastroepiploic artery, a turn is made to the 
left side. The right-sided thoracotomy in the V 
intercostal space and after revision of the pleural 
cavity, clarification of the extent of the tumour 
process, mobilises the oesophagus above the aortic 
arch with the intersection and ligation of the unpaired 
vein. At the same time, lymph node dissection is 
carried out, all mediastinal lymph nodes are removed 
to the cardiodiaphragmatic angle. After that, the 
stomach, along with the oesophagus, is pulled into the 
pleural cavity. After skeletonisation of the lesser 
curvature of the stomach, we produce a proximal 
resection of the stomach using UO-60, UO-40 
devices. The mechanical suture is covered with grey-
serous sutures. After resection of the oesophagus, 
proximal to a tumour 5 cm impose the oesophagal-
gastric submersible anastomosis. In view of the high 
resection of the esophagus with its significant 
mobilization, graft tension, extended lymph node 
dissection, 7 (3.27%) cases of oesophagal 
anastomosis insolvency were noted for 214 radical 
operations and 2 (0.93%) for transplant necrosis, in 
connection with what they decided to improve the 
method of imposing oesophagal anastomoses. 
Starting in 2012, they began to produce 
esophagoplasty for cancer with a “solid” stomach 
(patent of the committee for Intellectual property rights 
of the Ministry of Justice of the Republic of 
Kazakhstan No. 1449905 dated 04.24.2017, “Method 
of esophageal plasty for cancer with a “whole” 
stomach during resection of the thoracic part of 
esophagus”). 
After a right-sided thoracotomy during Lewis 
type surgery, pulling the oesophagus with the 
stomach into the pleural cavity, the oesophagus is 
resected 5 cm above a tumour. Then, only the 
cardinal part of the stomach is resected, immediately 
below the cardiac sphincter, a small part of the fundus 
of the stomach is partially resected, some 5 cm from 
the extreme short fundal artery. The resection of the 
stomach is performed using the apparatus of УО-60, 
УО-40. The mechanical suture is covered with grey-
serous sutures with the immersion of the nodes of the 
stomach stump into semi-set sutures, which later, 
after the imposition of the oesophagal anastomosis, 
act as a cardiac sphincter. Then an oesophagal-
gastric immersion anastomosis of the “end to side” 
type is formed. In this way, 113 operations were 
performed, 2 cases with complications (1.76 ± 1.23%), 
in one case, there was an insufficiency of the 
oesophagal anastomosis 0.88 ± 0.87%, and 1 graft 
necrosis 0.88 ± 0.87%, which have been lethal. 
The prevailing postoperative complication was 
congestive pneumonia, which was noted in 6.55% 
(24) cases. Postoperative mortality was 6.54% (14) for 
214 operations, of which in 7 cases (50.00%) there 
was a failure of the esophageal anastomosis, 5 
(35.71%)-cardiovascular disorders, 2 (14.29%), 
cardiopulmonary insufficiency (p < 0.05). 
The long-term results of treating patients with 
the thoracic part of oesophagal cancer were studied 
depending on the method of therapy and prognostic 
factors using survival. 
Statistical analysis was performed using 
Statistica version 10 software. All values are 
expressed as mean ± mistake or medians and 
interquartile ranges for continuous factors and 
frequencies for categorical factors. The one-
dimensional analysis was performed using Chi-square 
and Fisher probability tests for continuous variables. 
Student t-test was used for continuous factors. 
Survival 5-year and overall survival were compared 
between groups using Kaplan-Meier analysis and log-
ranking criteria. In a one-dimensional analysis of 
overall survival, variables with value were statistically 
rethought to adjust for concomitant factors. The coke 
model was used for multivariate regression analysis. 
A p-value less than 0.05 was considered statistically 
significant. 
 
 
Results 
 
The overall five-year survival, regardless of 
the method of treatment, was only 8.72% (28 of 321), 
and in 6-10 years lived 8.41% (27 of 321), p < 0.05. 
Analysis of the overall survival of patients with cancer 
of the thoracic part of oesophagus showed that the 
method of treatment does not have a significant 
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impact on life expectancy. 
Table 2: The total lifetime of patients with oesophagal cancer 
after radical treatment 
The 
number of 
observed 
patients 
Lifetime in years 
 321 
1 2 3 5 ˃5 
Abs. 
number 
% 
Abs. 
number 
% 
Abs. 
number 
% 
Abs. 
number 
% 
Abs. 
number 
% 
128 39.88 86 26.79 52 16.20 28 8.72 27 8.41 
 
From the analysis excluded patients who as 
of 01/01/2018, after treatment, the follow-up period 
was less than 2 years, 321 (87.7 ± 1.7) cases were 
analysed. 
A multifactor analysis of 19 gradations that 
affect the prognosis of the disease was carried out. 
Analysis of cumulative survival showed that (Figure 3) 
the best and 5-year survival was among patients in 
group 1, which was 26.53% (out of 147 treated, 5 
years lived 39). The median survival is 19 months. 
 
Figure 3: Lifetime with surgical treatment 
 
In the second group (Figure 4), the 5-year 
survival rate did not significantly exceed 8.57% (out of 
140 treated, 5 years survived 12). 
 
Figure 4: Radical radiation therapy 
 
The patients who underwent combined 
treatment (Figure 5) lived 5 years in 17.65% (out of 34 
treated, 5 years lived 6) cases. At the same time, it 
should be noted that the median of survival was the 
same with the surgical treatment group, and was 19 
months. 
 
Figure 5: Lifetime with combined treatment 
 
However, a comparative analysis of 
cumulative survival by Kaplan-Meier (Figure 6) 
showed that the best survival was reliably observed 
with surgical treatment (p < 0.05) than with radiation 
and combined treatment, the median survival was 
13.5 months. 
 
Figure 6: Cumulative survival depending on the method of 
treatment 
 
Such a low cumulative survival among 
patients of the 2nd and 3rd groups is because patients 
with high operational risk were subjected to radiation 
treatment. The leading cause of failure in surgical 
treatment was old age (over 70 years of age was 46.7 
± 4.05%) and cardiopulmonary insufficiency was 
11.84 ± 2.62. Whereas, in the 1st group, patients 
aged 51-60 years (46.38 ± 3.87%) with 
cardiopulmonary pathology prevailed in only 5.42% ± 
1.76% of cases. In the group of patients after 
combined treatment, 33.33 ± 6.8% of cases aged 51-
60 years with a cardiopulmonary pathology of 6.25 ± 
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3.49% (p < 0.05) prevailed. 
A mathematical model for assessing the risk 
of death in cancer of the oesophagus showed (Figure 
7), regardless of the method of treatment of cancer of 
the thoracic oesophagus, the risk of mortality 
increases in the first 2 years and increased 4 years 
after treatment. 
 
Figure 7: The risk of mortality in the treatment of oesophagal cancer 
 
 
 
Discussion 
 
According to most researchers [1], [2], [4], [5],  
[7], the prospects for the use of radiation and 
chemotherapeutic care for patients with distributed 
forms of esophageal cancer are limited in view of its 
resistance, and basically these types of treatment are 
of an auxiliary nature. The leading treatment for 
oesophagal cancer is surgical. 
According to reports [10], [11], oesophagal 
cancer has a high potential for lymphogenous 
metastasis and in case of a lesion of the submucosal 
layer, i.e. T1 metastases in the lymph nodes are 
detected in 40%, and during germination of adventitia, 
90%. 
According to Stilidi I. et al., so-called “jumping 
metastases” in regional and distant nodes are 
detected in 20%, and it is extremely difficult to 
determine the direction of lymphatic drainage. 
Therefore, a prerequisite, i.e. the standard for the 
surgical treatment of oesophagal cancer should be 
considered extended 2-hzonalny lymph node 
dissection [11]. 
One of the important prognostic factors 
affecting life expectancy is the frequency of damage 
to the lymphatic catch and their number [12]. The 3-
and 5-year survival in the presence of N1 was 47.7% 
and 12.9%, and at the stage of N0, it was 68.6% and 
54.8%, respectively (p < 0.05). Equally important for 
the forecast is the number of affected lymph nodes. 
The “critical” number is 7 affected lymph nodes [5], 
[12]. According to Napier K.J. et al., [12], and Stilidi 
I.S. et al., [11] none of the patients with 7 or more 
lymph nodes did live up to 3 years. 
Japanese surgeons from the 80s [13] used a 
three-zone lymphadenectomy, arguing that in 40% of 
patients with squamous cell carcinoma of the 
oesophagus after radical surgery, metastasis to the 
cervical lymph nodes is detected in the long term. 
According to the authors of [14], the 5-year survival 
rate after the above operations was 65% for 
squamous cell carcinoma and 46% for 
adenocarcinoma. The same data confirm Altorki N. et 
al., [14], who proved that 25% of patients experienced 
a 5-year follow-up, despite the presence of cervical 
metastatic lymph nodes. 
One of the most promising methods of 
combined treatment, according to N.V. Dengina [15] is 
neoadjuvant chemotherapy, in which resectability and 
patient survival are increased. The effectiveness of 
neoadjuvant chemotherapy followed by surgery, the 
author, estimates in 45-70% of cases. With radiation 
therapy in a total dose of 45-75 Gray in patients with 
small tumours, the 5-year survival rate does not 
exceed 10 to 15%. The author notes that radiation 
and chemotherapy are palliatives in nature. Therefore 
the use of the above methods as an independent 
method of treating oesophagal cancer is an alternative 
solution. 
The data obtained confirm the correlation 
analysis of Spearman, conducted in pairs with each 
group of patients, depending on the method of 
treatment and the presence of prognostic factors. 
According to the findings, affecting the 
outcome of treatment of esophageal cancer, factors 
such as tumour localization (rs = -0.089776), 
histological form (rs = -0.055125), regional lymph 
node metastases (rs = -0.0342697) effect , the length 
of the oesophagus tumour (rs = -0.248513) with a 
confidence interval of 95%. All of the above factors 
relate to the concept of the stage of the disease. 
However, among all the prognostic factors, the 
presence of regional metastases plays the most 
important role in the choice of treatment and the 
prognosis of a long-term outcome. For patients under 
60 years of age with regional metastases, the long-
term outcome in the combined degree (rs = 0.277693) 
is determined, as well as the tumour localization in the 
bronchial and retrocardial segment, it is equal to (rs = 
0.243261), the histological type is squamous cell 
cancer with keratinization ( rs = 0.164874), the length 
of the tumour is not more than 3 cm (rs = 0.311595), 
invasion of the muscle layer tumour (rs = 0.320403). 
Also, a lifetime in the long term depends on the 
factors of cancer recurrence and the progression of 
the process. Their relationship was, respectively, rs = 
-0.139073 and rs = 0.144985.  
Thus, the prognosis for the long-term 
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outcome of treatment for distributed cancer of the 
thoracic oesophagus depends on the stage of the 
disease, the location of the tumour and the presence 
of regional metastases. When the prehospital 
diagnosis of cancer localisation in the mid-thoracic 
oesophagus with a process length of more than 3 cm 
and the presence of regional metastases before the 
age of 65, it is necessary to plan a combined 
treatment (neoadjuvant radiation therapy + surgery). 
Radiation therapy for advanced cancer of the thoracic 
oesophagus is palliative in nature and should mainly 
be used in patients older than 70 years with 
comorbidities in the decompensation stage. 
In conclusion, a radical treatment for cancer 
of the mid- and lower thoracic oesophagus is surgical, 
in which the median of cumulative survival is 19 
months. Traditional radiation therapy should be 
applied in a limited way, as it is palliative in nature, the 
median survival rate does not exceed 9 months. 
In the presence of regional metastases in 
cancer of the thoracic oesophagus, it is advisable to 
use the combined method (neoadjuvant radiation 
therapy + Lewis surgery with 2-zonal dissection), the 
median survival is 19 months. 
The leading prognostic factor for cancer of the 
thoracic region is the presence of regional 
metastases, on which the choice of treatment 
depends. With an inadequate choice of treatment 
method in a long-term period, the frequency of 
relapses and progression of the tumour process 
increases. Especially high-risk mortality in the first 2 
years after treatment, regardless of the method of 
treatment of cancer of the thoracic oesophagus. 
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